Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.

A transdermal device (1) comprising at least one substrate (2) arranged to be applied against the dermal surface or the mucous membrane. The at least one active ingredient is grafted to the substrate (2) by at least one photolabile ligand, and at least one light source (11) operated by a control mechanism arranged to generate light pulses, of a predetermined wavelength, intended to break covalent bonds between the active ingredient and the ligand in order to release the active ingredient from the substrate (2). The substrate (2) comprises at least one porous matrix (6) with a three-dimensional structure comprising a plurality of pits (7) organized in a sponge-like fashion and constructed of a polymer chosen between chitin and chitosan, and the matrix (6) defines at least one three-dimensional tank (8). The active ingredient is contained and grafted by the ligand.

There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use.

The invention relates to a pharmaceutical composition consisting of snail slime Helix aspersa muller (Cryptomphalus aspersus) (20% to 50%), camomile extract (1-4%), propolis 1l-4%), and pharmaceutically acceptable excipients and/or additives for forming a formulation of low, intermediate or high viscosity (10 to 1000 Pa-s). Said composition is in the form of a lotion, soap, cream or gel, which is embedded in a gauze-type fabric in the form of a plaster that can be applied to lesions caused by the different types of rosacea. The composition can also contain natural extracts such as marigold extract, honey and vegetable oils. The invention also relates to the method for producing the composition and to the use thereof for preparing a medicament or device for preventing, treating or curing lesions caused by rosacea, on the skin of the face or the body.

A transdermal patch for use in auriculotherapy containing at least one active substance selected from caffeine, chocolate and glutamine for the modulation of neurotransmitters. The transdermal patch contains at least one ingredient selected from L-tyrosine, phenylalanine, 5-htp decarboxylase, 5-hydroxy-tryptophane, tryptophan, theobromine, anandamide, phenylethylamine, gamma hydroxybutyrate acid, gamma hydroxybutyric acid, GABA transaminase, theanine, taurine, homotaurine, melatonin, carnitine, acetyl-carnitine, S-Adenosylmethionine, N-acetyl L-cysteine, N-acetyl-transferase, phosphatidylserine, inositol, phosphatidylinositol, catalase, dopamine beta-hydroxylase, L-dopa descarboxylase, NADH, magnesium, zinc, manganese, chromium, copper, selenium, iron, calcium, lithium, calcium citrate, vitamin C, vitamin B, coenzyme Q10, omega-3, ashwagandha, Melissa oficinalis, Siberian ginseng, St. John's wort, valerian, Ginko biloba, Mucuna pruriens, turmeric, Rhodiola rosea and Bacopa monniera extracts.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Pharmaceutical compositions and methods for treating and/or preventing and/or control of Parkinson's Disease and/or related symptoms in a patient.